Protocol Ledger

NCT07387549 · Phase III · RECRUITING

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

Interventional Phase III clinical trial protocol NCT07387549 sponsored by Ipsen in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-05-14 Enrollment: 350 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07387549
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)350 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07387549
Protocol FieldVerified Registry Value
NCT IdentifierNCT07387549
Consolidated Lead SponsorIpsen
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment350 participants (ESTIMATED)
Registered Start Date2026-05-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI